Actively Recruiting
Randomized Study of APC-0101 Surfactant Inhalation Therapy Versus Sham in Preterm Infants with Respiratory Distress Syndrome
Led by Aerogen Pharma Limited · Updated on 2026-10-13
520
Participants Needed
31
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of APC-0101, a surfactant for inhalation delivered with a special device, in preterm infants with Respiratory Distress Syndrome RDS. This phase 3, randomized, blinded, sham-controlled study compares infants treated with APC-0101 plus standard non-invasive respiratory support nCPAPNIV to those treated with the respiratory support alone. The study aims to better understand treatment outcomes in this vulnerable population. Participants are randomly assigned to either receive APC-0101 treatment with a dedicated delivery system alongside their current nCPAPNIV interface or to a control group where the nCPAPNIV interface is switched but no active surfactant is given sham. The study has two parts Part 1 follows infants until they reach 40 weeks post-menstrual age or are discharged from the neonatal intensive care unit, whichever comes first. In Part 2, infants are followed up until 24 months corrected age to assess longer-term outcomes. During the study, infants receive respiratory support and may be monitored with chest X-rays or lung ultrasounds to confirm RDS. Researchers will track treatment failure during the first 7 days of life and record the use of surfactant doses in the first 72 hours. The follow-up period includes evaluations up to 24 months to assess growth and health outcomes. Participation includes randomization, treatment administration, and extended follow-up visits to monitor safety and development.
CONDITIONS
Brief Title
Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
Research Team
M
Medical Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here